480
Participants
Start Date
January 5, 2024
Primary Completion Date
April 3, 2027
Study Completion Date
April 3, 2027
SIRI Team
"Participants randomized to the intervention will receive integrated ID and SUD care (SIRI Team) both during the hospitalization and after hospital discharge for 4 months post-randomization. The intervention is based upon six general principles for treating PWID with infectious complications and is informed by harm reduction.~1. Medications for SUD as integral to management of infectious complications~2. Integration of ID and SUD care~3. Longitudinal care with familiar providers~4. Multidisciplinary care and care coordination~5. Tailored antibiotic options and care settings~6. Harm reduction"
Treatment as Usual
Participants assigned to the TAU group will receive the standard treatment for their severe injection-related infection and substance use disorder at each hospital. While TAU may differ between sites, it is typically comprised of a patient being cared for primarily by a hospital medicine physician (hospitalist) with consultation by infectious diseases (ID) and either psychiatry or addiction medicine physician. If the ID or addiction teams believe post-hospitalization follow up is indicated, each service will follow local protocols for arranging post-discharge continuation of care.
University of Pennsylvania, Philadelphia
University of Miami - Jackson Memorial Hospital, Miami
Tampa General Hospital, Tampa
University of Alabama at Birmingham, Birmingham
University of Utah Hospital, Salt Lake City
University of New Mexico Health Sciences Center, Albuquerque
University of Miami
OTHER
Emory University
OTHER
National Institute on Drug Abuse (NIDA)
NIH
The Emmes Company, LLC
INDUSTRY
Columbia University
OTHER